The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity

Dahoun, Tarik
2018-10-15


http://hdl.handle.net/10138/286193
https://doi.org/10.1093/hmg/ddy242

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study

Tarik Dahoun1,2,3, Antonio F. Pardiñas4, Mattia Veronese5, Michael A.P. Bloomfield1,2,6,7,8, Sameer Jauhar1,2,6, Ilaria Bonoldi1,2,6, Sean Froudist-Walsh9, Chiara Nosarti14,15,16,†, Carsten Korth10, William Hennah11,12,13, James Walters4, Diana Prata14,15,16,† and Oliver D. Howes1,2,6,*,†

1Psychiatric Imaging Group, Robert Steiner MRI Unit, MRC London Institute of Medical Sciences, 2Faculty of Medicine, Institute of Clinical Sciences (ICS), Imperial College London, Hammersmith Hospital, London W12 0NN, UK, 3Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford OX3 7JX, UK, 4Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK, 5Centre for Neuroimaging Sciences, 6Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, London SE5 8AF, UK, 7Division of Psychiatry, University College London, London WC1T 7NF, UK, 8Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London WC1E 6BT, UK, 9Center for Neural Science, New York University, New York, NY 10003, USA, 10Department Neuropathology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany, 11Institute for Molecular Medicine Finland FIMM, University of Helsinki, 00014 Helsinki, Finland, 12Mental Health Unit, Department of Health, National Institute for Health and Welfare, 00271 Helsinki, Finland, 13Medicum, University of Helsinki, 00014 Helsinki, Finland, 14Instituto de Biofisica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal, 15Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UK, 16Instituto Universitário de Lisboa (ISCTE-IUL), Cis-IUL, Lisbon, Portugal and 17Division of Imaging Sciences & Biomedical Engineering, Centre for the Developing Brain, King’s College London, London, UK

*To whom correspondence should be addressed at: Institute of Clinical Sciences (ICS), Psychiatric Imaging Group, MRC Clinical Sciences Centre, Imperial College - Hammersmith Hospital Campus, London W12 0NN, UK. Tel: ++44 2083833446; Fax: ++44 2083831783; Email: oliver.howes@kcl.ac.uk

Abstract

Whilst the role of the Disrupted-in-Schizophrenia 1 (DISC1) gene in the aetiology of major mental illnesses is debated, the characterization of its function lends it credibility as a candidate. A key aspect of this functional characterization is the...
determination of the role of common non-synonymous polymorphisms on normal variation within these functions. The common allele (A) of the DISC1 single-nucleotide polymorphism (SNP rs821616 encodes a serine (ser) at the Ser704Cys polymorphism, and has been shown to increase the phosphorylation of extracellular signal-regulated protein Kinases 1 and 2 (ERK1/2) that stimulate the phosphorylation of tyrosine hydroxylase, the rate-limiting enzyme for dopamine biosynthesis. We therefore set out to test the hypothesis that human ser (A) homozygotes would show elevated dopamine synthesis capacity compared with cysteine (cys) homozygotes and heterozygotes (TT and AT) for rs821616. \[^{18F}\]DOPA positron emission tomography (PET) was used to index striatal dopamine synthesis capacity as the influx rate constant \(K_{i}^{cys}\) in healthy volunteers DISC1 rs821616 ser homozygotes (N = 46) and healthy volunteers DISC1 rs821616 cys homozygotes and heterozygotes (N = 56), matched for age, gender, ethnicity and using three scanners. We found DISC1 rs821616 ser homozygotes exhibited a significantly higher striatal \(K_{i}^{cys}\) compared with cys homozygotes and heterozygotes (\(P = 0.012\) explaining 6.4% of the variance (partial \(\eta^2\) = 0.064). Our finding is consistent with its previous association with heightened activation of ERK1/2, which stimulates tyrosine hydroxylase activity for dopamine synthesis. This could be a potential mechanism mediating risk for psychosis, lending further credibility to the fact that DISC1 is of functional interest in the aetiology of major mental illness.

Introduction

The dopamine hypothesis has been a leading theory underlying the neurobiology of schizophrenia for the last four decades (1,2). The hypothesis was initially based on evidence showing that antipsychotic medications block dopamine receptors (3-5) and that drugs increasing dopamine levels elicit psychotic symptoms in healthy people (6-8) and people with schizophrenia (9,10). Using \[^{18F}\]fluoro-3,4-dihydroxyphenyl-L-alanine (F-DOPA) positron emission tomography (PET), increased presynaptic dopamine synthesis capacity has been found in schizophrenia (11), people with prodromal psychotic symptoms (12,13) and those with clinical progression to psychosis (14). Whilst a substantial body of evidence supports the role of increased presynaptic dopamine synthesis capacity in the pathoetiology of psychosis, little is known about how genetic factors affect the implicated dopamine system(s) (15).

The Disrupted-in-Schizophrenia 1 (DISC1) gene was originally discovered at the breakpoint of a balanced t(1;11) (q42; q14.3) translocation in a Scottish family with a high-prevalence of psychiatric disorders including schizophrenia (15-18). Further evidence for a link between DISC1 and psychotic and affective disorders emerged from the follow-up of families displaying rare DISC1 mutations (19,20) and large family-based studies in the population isolate of Finland (21-23) although a large meta-analysis of families did not observe linkage at this region (24). Furthermore, evidence from individual population-based cohorts has been inconsistent (25,26) leading to ongoing debate on its involvement in schizophrenia (27,28). Whilst this controversy remains unresolved, there is value in seeking convergent evidence via studies elucidating the functional impact of the gene and its variations (29-32). DISC1 is a scaffold protein involved in a wide range of neuronal functions including neuro-signalling (30,33). Preclinical studies show that DISC1 variant models exhibit increased amphetamine-induced dopamine release in the ventral striatum [see (34-37) reviewed in (38)], indicating that DISC1 variations might affect presynaptic dopamine synthesis capacity.

One of the most studied DISC1 single-nucleotide polymorphisms (SNPs) is rs821616 which is a non-synonymous mutation leading to the translation of a serine (ser) (A allele) or a cysteine (cys) (T allele) at codon 704 in exon 11 (39). Importantly, this polymorphism represents therefore not only a variation at the genetic sequence level but also at the protein sequence level of DISC1. At a molecular level, Hashimoto et al. (47) found that overexpression of the ser variant of codon 704 by viral transduction resulted in a significant increase in phosphorylated Extracellular signal-regulated protein Kinases 1 and 2 (ERK1/2), the more biologically active form (40). ERK1/2 in turn regulates the state of phosphorylation of tyrosine hydroxylase, the rate-limiting enzyme for dopamine biosynthesis, to increase its activity and subsequent dopamine synthesis by up to 2-fold (41-44). Dopamine is synthesized by converting first tyrosine into dihydroxyphenyl-L-alanine (L-DOPA) by tyrosine hydroxylase, and second dihydroxyphenyl-L-alanine (L-DOPA) into dopamine by aromatic acid decarboxylase (AADC) (45). \[^{18F}\]DOPA PET signal reflects AADC function and dopamine storage capacity (45), but not directly tyrosine hydroxylase function. However, it should be noted that (i) tyrosine hydroxylase is the rate limiting step for dopamine synthesis capacity (43) and (ii) the topological distribution of the \[^{18F}\]DOPA signal correlates highly with tyrosine hydroxylase immunostaining in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats, thus indicating that the \[^{18F}\]DOPA signal is strongly influenced by endogenous dopamine formed by tyrosine hydroxylase (46).

In summary, preclinical findings suggest that the Ser704Cys variation affects dopamine synthesis by regulating ERK1/2 and its control over tyrosine hydroxylase activity. However, it remains unknown whether the Ser704Cys variation is associated with altered dopamine synthesis in humans. The aim of this study was therefore to test the hypothesis that ser homozygotes would exhibit increased striatal dopamine synthesis capacity relative to cys homozygotes and heterozygotes.

Results

Demographics, scan parameters including the injected dose and substance use characteristics are shown in Table 1. A total of 46 ser homozygotes and 56 cys homozygotes and heterozygotes (which encompass 45 heterozygotes and 11 cys homozygotes) were included in the study. The genotype frequencies (shown in Table 1) did not significantly deviate from Hardy-Weinberg equilibrium (\(\chi^2 = 1.422\) with \(P = 0.233\)), with a Minor Allele Frequency (T allele) of 0.335. Age (year) and \(K_{i}^{cys}\) were normally distributed across the two groups whereas injected dose (MBq) was not. There was no significant difference in age between groups t(100) = 1.588, \(P = 0.115\) (independent t test) and no significant difference in injected dose \(P = 0.408\) (Mann-Whitney U test). Levene’s test indicated no difference between the variances in the two groups, \(F = 0.398, P = 0.529\). The univariate analysis of covariance (ANCOVA) showed that the main effect of the DISC1 SNP rs821616 on the dopamine synthesis capacity in the striatum was significant, \(F(1,96) = 6.555, P = 0.012, partial \eta^2 = 0.064\) (Fig. 1). The effects of
and heterozygotes significantly increased in ser homozygotes compared with cys homozygotes.

**Limitations**

The main limitation of this study was that we used data from three different PET scanners, which could add error variance.

**Discussion**

In line with our hypothesis, we found that participants ser homozygotes (AA genotype) for the Ser704Cys functional DISC1 polymorphism exhibited a significantly greater $K_{\text{imm}}$ value in the striatum, indicating greater dopamine synthesis capacity compared with cys homozygotes and heterozygotes (AT or TT genotype). This result is in accordance with preclinical evidence showing that the ser 704 DISC1 variant increases the activity of ERK1/2, which in turn enhances the phosphorylation of tyrosine hydroxylase, the rate limiting step in dopamine synthesis (41, 47).

However, scanner was included as a covariate to adjust for this. Furthermore, the effect of the Ser704Cys polymorphism remained significant when we only included subjects from PET scanner 2 [$F(1, 28) = 5.273, P = 0.029$ (N = 16 cys homozygotes and heterozygotes, N = 17 ser homozygotes)], but not PET scanner 1 only [$F(1, 30) = 0.766, P = 0.388$ (N = 19 cys homozygotes and heterozygotes, N = 16 ser homozygotes)] and PET scanner 3 only [$F(1, 29) = 0.426, P = 0.519$ (N = 21 cys homozygotes and heterozygotes, N = 13 ser homozygotes)]. It is important to recognize that we measured the final step in the synthesis of dopamine, the conversion of L-DOPA into dopamine via AADC. However, the parameter measured could be affected by other variables including the uptake of L-DOPA into dopamine via AADC. Therefore, there was evidence to reject the null hypothesis, the $P$-value would not survive genome-wide correction and therefore the result requires replication.

**Implications for mental disorders**

The Ser704Cys polymorphism has been associated with schizophrenia with an odds ratio in the range of 1.3–4.18 in various populations including European (48), mixed European/African-American (49) and Chinese Han (50–52). Inconsistencies have been found, with some studies indicating increased risk associated with the ser (A) allele (48, 51), whilst others the cys (T) allele (50, 52) and no association found (25) mainly in the Japanese population (53–55). A recent meta-analysis has also reported association of the ser allele with schizophrenia in Chinese (OR $= 1.338$) and Japanese populations (OR $= 1.524$), as well as in the overall mixed race sample (56). The inconsistencies in these results might be owing to different ethnic populations. It should be noted that ever expanding studies of European ancestry population level genetic variants in schizophrenia continually demonstrate no significant associations at the entire DISC1 locus (57, 58), although there is evidence implicating the DISC1 interactor phosphodiesterase 4B as a...
The DISC1 protein has been associated with increased risk for psychosis (12,13). The difference in dopamine synthesis capacity we observe here between ser homozygotes and carriers of the alternative allele is much smaller than the differences seen in at risk subjects (14,66). It is therefore likely that the Ser704Cys variant interacts with other genetic changes to mediate risk, potentially by affecting dopamine synthesis.

The fact that the common ser allele has been described as the risk allele is compatible with schizophrenia GWAS, in which ~50% of the implicated index SNPs are the more common alleles (67). At the population level, the genetic susceptibility to schizophrenia is caused by a few rare variants of high penetrance (mainly copy number variants and translocations) and many common variants of small penetrance (SNPs and variable number of tandem repeats) (68). As each SNP very minimally impacts schizophrenia risk and is compatible with modern models of natural selection (67), it is expected that other genetic factors are needed, in the same individual, to increase the liability to a point of schizophrenia onset. For example, the Ser704Cys site affects interaction with nuclear distribution element-like 1 (NDEL1) and its homolog Nuclear Distribution Element 1 (NDE1, also known as NudE) (69,70), and there is evidence for an interaction between NDEL1 rs1391768 and the Ser704 allele and the NDE1 rs3784859 and the Cys704 allele on the risk for schizophrenia in European participants (71). Ser704Cys is also the binding site for proteins such as kendrin [also known as pericentrin (PCNT)] and Pericentriolar material 1 (72), which have been both described as risk factor genes for schizophrenia (73). Furthermore, environmental factors such as exposure to psychosocial stress may also interact with the Ser704Cys polymorphism to affect dopamine function and mediate risk for schizophrenia (15). Interestingly, using a transgenic expression of truncated human Disc1 protein with dominant-negative effect, Niwa et al. have shown that an interaction between DISC1 and stress exposure, as a 3-week social isolation paradigm, increased dopamine release after amphetamine challenge (34) and induced alterations in DNA methylation of the tyrosine hydroxylase gene (74).

Evidence also suggests that the Ser704Cys polymorphism is a risk factor for affective disorders. The cys allele has been associated with major depression in Japanese population (47), and shown to form a protective haplotype for bipolar spectrum disorder with two others DISC1 SNPs (rs1411771 and rs980989) in Finnish population (75), whereas a higher ser allele rate has been found in South Indian population with bipolar disorder (76). Interestingly, increased dopamine synthesis capacity is seen in both mania (77) and bipolar psychosis (78), whilst major depression with affective flattening is characterized by a decreased synthesis capacity (79,80).

The Ser704Cys SNP has also been shown to have a functional impact at the brain level (39). Compared with healthy cys homozygotes and heterozygotes, ser homozygotes display increased (for the same level of performance, thus putatively inefficient) prefrontal cortex activation in the left middle and left superior frontal gyri and in the homologous right superior frontal gyrus, the left inferior frontal and cingulate cortex, the thalamus and the caudate nucleus in a verbal fluency task (81), as well as an effect on thalamic-prefrontal connectivity (82). Ser704Cys SNP has also been shown to affect activation during declarative memory task with inconsistent findings. Callicott et al. (48) found decreased activation bilaterally in the hippocampal formation during a declarative memory task and increased activation bilaterally in the hippocampal formation in an N-back task in ser704 homozygotes controls compared with cys homozygotes and heterozygotes, whereas Di Giorgio et al. (83) found increased hippocampal formation/dorsolateral prefrontal cortex coupling during memory encoding in a declarative memory task in ser homozygotes compared with healthy cys homozygotes and heterozygotes.

In summary, our results provide unprecedented preliminary evidence that DISC1 Ser704Cys has an impact on the dopamine synthesis capacity, in a large sample of 102 healthy volunteers. Further studies should aim at (i) replicating this result in different cohorts; (ii) investigating potential epistatic interactions with DISC1 and other risk genes. Genetic studies based on molecular evidence could help identify the molecular mechanism that underlies the pathoaeiology of dopamine-related disorders such as psychotic disorders, and help identify novel potential treatment targets (15).

**Conclusion**

We found that the ser allele of DISC1 Ser704Cys (rs821616) was associated with significantly higher striatal dopamine synthesis capacity, consistently with its previous association with heightened activation of ERK1/2 that stimulates tyrosine hydroxylase activity for dopamine synthesis. This implicates the DISC1 polymorphism in altering a psychosis relevant mechanism in the brain, i.e. the facilitation of greater dopamine synthesis capacity. Although, this effect of rs821616 may be of too small effect to be identified in population-based studies of end state diagnoses at their current large size, it continues to implicate the functional role of DISC1. Firstly by highlighting the role of this polymorphism at this gene in creating variation within the normal functioning of the brain, but also by indicating this function as a potential mechanism through which other rare or familial mutations for major mental illnesses could disrupt functioning and increase risk to these devastating disorders.

**Materials and Methods**

**Overview**

All participants gave informed written consent to take part after full description of the study. All studies were approved by the institutional review board and the local research ethics committee.
Participants

Participants were recruited via advertisement in local media based in London. One hundred and twenty-three participants underwent a $[^{18}F]$-DOPA PET scan. For all participants the inclusion criteria were (i) age above 18 years; (ii) capacity to give written informed consent. The exclusion criteria were (i) any current medical conditions or history of medical condition (past minor self-limiting conditions were permitted); (ii) history of a psychiatric disorder as determined by the Structured Clinical Interview for DSM-IV Axis 1 Disorders, Clinician Version (SCID-CV) (84); (iii) history of substance abuse/dependence as determined by the Structured Clinical Interview for DSM-IV Axis 1 Disorders, Clinician Version (SCID-CV) (84); (iv) history of head injury with a loss of consciousness; (v) a family history of any psychotic disorder in first- or second-degree relatives; (vi) contraindications to PET scanning (significant prior exposure to radiation, pregnancy or breast feeding). All participants provided urine samples prior to the scan to screen for drug use and pregnancy test in women. Six participants were excluded owing to positive urine THC screening, 12 participants were excluded to contamination of samples and 3 participants were excluded owing to current psychotropic medication use. This resulted in the final inclusion of 102 participants (46 females/56 males, age: $30.2 \pm 9.3$ years, mean $\pm$ Standard Deviation). Both scanning and imaging analysis were done blind to the genotype status.

$[^{18}F]$-FDOPA PET

PET data were acquired using three different PET scanners. PET scanner 1 was an ECAT HR+ 962 PET scanner (CTI/Siemens, Knoxville, TN, USA). The dynamic images were acquired in 3D mode with an axial field of view of 15.5 cm and reconstructed using filterback projection. PET scanners 2 and 3 were two Siemens Biograph HiRez XVI PET-CT scanner (Siemens Healthcare, Erlangen, Germany) at Imanova, Centre for Imaging Sciences. PET scanner 1 and PET scanner 2–3 were identical with the only exception of the axial field of view: 16.2 versus 21.6 cm, respectively. The dynamic images were also reconstructed using a 3D filtered back-projection algorithm (discrete inverse Fourier transform, DIFT) with a 128 matrix, a zoom of 2.6 and a 5 mm isotropic Gaussian smoothing. Participants were scanned at various times of the day. Some of the imaging data has been included in prior reports but not for genetic analysis (85–88). For attenuation and model-based scatter correction, a 10 min transmission scan was performed using a 150-MBq cesium-137 rotating point source for the ECAT HR+. 962 PET scanner and a computed tomography scan (effective dose $= 0.36$ mSv) for the Siemens Biograph HiRez XVI PET-CT scanners were acquired prior to each PET scan. Experimental protocol was consistent for all the participants (85). Participants were asked to fast and abstain from smoking from midnight on the day of the scan as tobacco use has been associated with increased striatal dopamine synthesis capacity (89) although this has not been replicated (85). Oral doses of carbidopa (150 mg) and entacapone (400 mg) were administered 1 h before scanning. While the first reduces the peripheral metabolism of the tracer (90), the latter minimizes the formation of radiolabelled $[^{18}F]$-DOPA metabolites, which can cross the blood–brain barrier (91). Head movement was monitored and minimized with a light head strap. If participants moved extensively during the acquisition or got out of the scanner a second attenuation correction image was acquired at the end of the acquisition. PET data were acquired dynamically during 95 min after bolus injection of the radioactive tracer $[^{18}F]$-DOPA through a cannula inserted into a vein. Dynamic data were binned into 26 frames (PET scanner 1) and 32 frames (PET scanner 2 and 3).

Image analysis

Head movement was corrected using a frame-by-frame realignment and denoising algorithm (92) with a level 2 order 64 Battle–Lemarie wavelet filter applied on the non-attenuation-corrected dynamic images. These images were used because they include a significant scalp signal compared with attenuation-corrected images (93). Frames were realigned to a reference frame corresponding to the frame with the highest number of counts, i.e. obtained 7 min (for the ECAT HR+ 962 PET scanner-CTI/Siemens) and 17 min (for the Siemens Biograph HiRez XVI PET-CT scanners, Siemens Healthcare) after the radiotracer injection using a mutual information algorithm (94). The transformation parameters were then applied to the corresponding attenuation-corrected dynamic images. These realigned frames were summed, creating a movement-corrected dynamic image from which to extract the time activity curves for graphical analysis quantification. Standardized regions in Montreal Neurologic Institute space were defined in the striatum delineated as previously described to create a region of interest (ROI) map (95) and in the cerebellum using the probabilistic Martinez atlas (95,96). The cerebellum was used as a reference region as it is largely devoid of dopaminergic neurons or projections (45). A non-linear transformation procedure on SPM8 (http://www.fil.ioi.ucl.ac.uk/spm) was used to normalize the ROI map together with the $[^{18}F]$-DOPA template to each individual PET summation image, in order to place the ROI automatically on individual $[^{18}F]$-DOPA PET dynamic images. Influx constant $K_{\text{in}}$ value (min $^{-1}$) for the striatum was calculated relative to uptake in the reference region using a graphical approach (97), a method which has been shown to have good reliability (95).

Genetic analysis

DNA was extracted from blood or cheek swabs using standard methods (98). Genotyping of the rs821616 A>T SNP, was performed by KBioscience (Herts, UK, http://www.kbioscience.co.uk) using a competitive allele-specific polymerase chain reaction system. Quality control procedures included negative control (water) wells and duplicate wells.

Statistical analysis

The normality of the distribution for all variables was examined using the Shapiro–Wilk test, inspection of Q–Q plots and skewness and kurtosis values within range of $\pm 2$. Homogeneity of variance was assessed with Levene’s Test for Equality of Variances. An alpha threshold was set at 0.05 (two-tailed) for significance for all statistical comparisons. Statistical Package for the Social Sciences version 24 was used for all statistical analysis (IBM, Armonk, NY, USA). All data are shown as mean $\pm$ SD. An univariate ANCOVA was performed on 102 healthy controls, with the DISC1 SNP Ser704Cys variation (ser homozygotes versus cys homozygotes and heterozygotes) as the independent variable, $K_{\text{in}}$ in the striatum as the dependent variable and age, gender, ethnicity (Table 1) and the three PET scanners separately as covariates as these variables have been previously found to influence dopamine synthesis capacity (99,100). Effect sizes are reported as partial $r^2$. Independent t test
and Mann-Whitney U test were used to compare age and injected dose.

Acknowledgements

We thank participants, all the staff at GE Imanet and Imanova for their assistance with this study and Lucinda Hopkins for assistance with genotyping.

Conflict of Interest statement. D.F. is a co-founder of the neuroimaging services company NeuroPsyAI, Ltd. O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, AstraZeneca, Autifony, Biogen, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither Dr Howes nor his family have been employed by or have holdings/a financial stake in any biomedical company. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. All other authors do not declare any conflict of interest.

Funding

This work was supported by an EU-FP7 MC-ITN IN-SENS grant (grant number 607616) to T.D., O.D.H., C.K., W.H. T.D. was supported by the National Institute for Health Research (NIHR) at Oxford Health NHS Foundation Trust. A.F.P. and J.W in Cardiff University were supported by funding from the Medical Research Council (MRC) Centre (MR/L011794/1), Program Grant (G0800509) Project Grant (MR/L010305/1), Program Grant (MC-A656-5QD30) and Medical Research Council (MR/K004867/1). M.V. was supported by the National Institute for Health Research Fellowship (NIHR, Academy of Finland Grant (No. 259589). D.P. was supported by a Biomedical Research Centre. W.H. was supported by an Academy of Finland Grant (No. 259589). C.K. was supported by a grant from the Research Commission of the Medical Faculty of the Heinrich Heine University Düsseldorf (#977251). C.N. was supported by March of Dimes Foundation (MC-A656-5DD30) and Medical Research Council (MR/K004867/1). M.A.P.B. was supported by the NIHR, British Medical Association (BMA) and the UCL Hospitals Neurosciences Biomedical Research Centre. W.H. was supported by an Academy of Finland Grant (No. 259589). D.P. was supported by a UK National Institute for Health Research Fellowship (NIHR, PDF-2010-03-047), a Marie Curie Career Integration Grant (FP7-PEOPLE-2013-CIG-631952) and a Fundação para Ciência e Tecnologia (FCT) Investigator grant (IF/00787/2014). O.D.H. was supported by Medical Research Council-UK (No. MC-A656-5QD30), Maudsley Charity (No. 666), Brain and Behavior Research Foundation, and Wellcome Trust (No. 094849/Z/10/Z) grants and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.

References


